Matthew Kulke

Matthew Kulke is an American cancer researcher. He is the Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and "Zoltan Kohn Professor" at the Boston University School of Medicine.[2][3] His work has shed light on the molecular characteristics of neuroendocrine tumors and has led to the development of multiple new treatments for this condition.[4][5] His research studies led to the development and approval of telotristat ethyl, a tryptophan hydroxylase inhibitor,[6] for the treatment of patients with carcinoid syndrome.[7] He has also contributed to early and late stage clinical trials of temozolomide, sunitinib,[8] everolimus, and peptide receptor radiotherapy for neuroendocrine tumors.[9][10]

Matthew Helmut Kulke
Alma materPrinceton University
UCSF School of Medicine
Harvard Medical School
Occupation(s)Chief of Hematology/Oncology, co-director of the BU/BMC Cancer Center and Zoltan Kohn Professor at the Boston University School of Medicine.
Years active1992-Present[1]

Education

Kulke received his undergraduate degree from Princeton University, his M.D. from the University of California, San Francisco School of Medicine, completed a residency in internal medicine at Brigham and Women's Hospital and a fellowship in Medical Oncology at Dana-Farber Cancer Institute.[10] He holds a master's degree in medical science from Harvard Medical School.[10]

Career

After his education, Kulke subsequently joined the faculty at Dana-Farber Cancer Institute and Harvard Medical School[11] where he rose to the rank of Professor of Medicine and was the founding director of the neuroendocrine tumor program.[5] He has served in his current role at Boston University since 2018. His accomplishments in the field have been recognized at the national and international level. He has served as chair of the National Cancer Institute's Neuroendocrine Tumor Task Force from 2011-2014,[12] as chair of the North American Neuroendocrine Tumor Society from 2014-2016, and as chair the National Comprehensive Cancer Network’s neuroendocrine tumor guidelines committee from 2010-2017.[5]

References
  1. "Dr. Matthew Kulke, MD". Health Grades. Retrieved 2020-11-19.
  2. "Matthew Helmut Kulke, MD". Boston University. Retrieved 2020-11-13.
  3. "Matthew Kulke, MD, Joins BUMC". Boston University School of Medicine. 2017-11-21. Retrieved 2020-11-20.
  4. Strosberg, Jonathan; El-Haddad, Ghassan; Wolin, Edward; Hendifar, Andrew; Yao, James; Chasen, Beth; Mittra, Erik; Kunz, Pamela L.; Kulke, Matthew H.; Jacene, Heather; Bushnell, David; o'Dorisio, Thomas M.; Baum, Richard P.; Kulkarni, Harshad R.; Caplin, Martyn; Lebtahi, Rachida; Hobday, Timothy; Delpassand, Ebrahim; Van Cutsem, Eric; Benson, Al; Srirajaskanthan, Rajaventhan; Pavel, Marianne; Mora, Jaime; Berlin, Jordan; Grande, Enrique; Reed, Nicholas; Seregni, Ettore; Öberg, Kjell; Lopera Sierra, Maribel; et al. (2019-01-12). "Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors". New England Journal of Medicine. 376 (2): 125–135. doi:10.1056/nejmoa1607427. PMC 5895095. PMID 28076709.
  5. "MATTHEW H. KULKE, MD". NANETS. Retrieved 2020-11-19.
  6. Pavel, Marianne; Gross, David J.; Benavent, Marta; Perros, Petros; Srirajaskanthan, Raj; Warner, Richard R P.; Kulke, Matthew H.; Anthony, Lowell B.; Kunz, Pamela L.; Hörsch, Dieter; Weickert, Martin O.; Lapuerta, Pablo; Jiang, Wenjun; Kassler-Taub, Kenneth; Wason, Suman; Fleming, Rosanna; Fleming, Douglas; Garcia-Carbonero, Rocio (2018). "Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial". Endocrine-Related Cancer. 25 (3): 309–322. doi:10.1530/ERC-17-0455. PMC 5811631. PMID 29330194. Retrieved 2020-11-20.
  7. Kulke, Matthew H.; Hörsch, Dieter; Caplin, Martyn E.; Anthony, Lowell B.; Bergsland, Emily; Öberg, Kjell; Welin, Staffan; Warner, Richard R.P.; Lombard-Bohas, Catherine; Kunz, Pamela L.; Grande, Enrique; Valle, Juan W.; Fleming, Douglas; Lapuerta, Pablo; Banks, Phillip; Jackson, Shanna; Zambrowicz, Brian; Sands, Arthur T.; Pavel, Marianne (2017-01-01). "Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome". Journal of Clinical Oncology. 35 (1): 14–23. doi:10.1200/JCO.2016.69.2780. PMID 27918724. Retrieved 2020-11-20.
  8. Kulke, Matthew H.; Lenz, Heinz-Josef; Meropol, Neal J.; Posey, James; Ryan, David P.; Picus, Joel; Bergsland, Emily; Stuart, Keith; Tye, Lesley; Huang, Xin; Li, Jim Z.; Baum, Charles M.; Fuchs, Charles S. (2008). "Activity of Sunitinib in Patients With Advanced Neuroendocrine Tumors". Journal of Clinical Oncology. 26 (20): 3403–3410. doi:10.1200/JCO.2007.15.9020. PMID 18612155.
  9. Abbott, Amanda; Sakellis, Christopher G.; Andersen, Eric; Kuzuhara, Yuji; Gilbert, Lauren; Boyle, Kelly; Kulke, Matthew H.; Chan, Jennifer A.; Jacene, Heather A.; Van Den Abbeele, Annick D. (2018-08-03). "Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division". Journal of Nuclear Medicine Technology. 46 (3): 237–244. doi:10.2967/jnmt.118.209148. PMID 30076245. S2CID 51909664. Retrieved 2020-11-20.
  10. "Matthew H Kulke, MD". Boston Medical University. Retrieved 2020-11-13.
  11. "MATTHEW H. KULKE, MD". Dana Farber/Harvard Cancer Center. Retrieved 2020-11-14.
  12. "Executive Summary of the National Cancer Institute Neuroendocrine Tumor Clinical Trials Planning Meeting" (PDF). Cancer.gov. Retrieved 2020-11-14.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.